Clinical Trial Update: A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial of VELCADE (bortezomib) in combination with gemcitabine for relapsed or refractory aggressive B- and T-cell non-Hodgkin's lymphoma; study termi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Velcade (bortezomib)

Snippet

Sponsor: Northwestern University | Conditions: Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-05-28